We're Making News

Jerusalem, Israel, October 1, 2017 - Immunity Pharma, a privately-held neurology-focused biopharmaceutical company, announced today that Mr. Ron Pfeifer was appointed as the chairman of its Board of Directors, after serving as a director since 2015. Mr. Pfeifer is an established investor with a track record of investing in dozens of breakthrough technology companies.

"Immunity Pharma’s excellent execution track record has led to its steady progress and the achievement of all its development goals to date. Immunity Pharma demonstrates how business innovation can support progress in biopharmaceutical development. I am confident that a success of our upcoming clinical trial will bring hope to people suffering from ALS as well as lead Immunity Pharma to a great business success" Said Mr. Pfeifer.

"Since joining the Board in 2015 Ron contributed significantly to the company and had a key role in securing its financing. His leadership and determination will be essential for driving Immunity Pharma’s future business growth and success," said Oren M. Becker, PhD, a co-founder and director of Immunity Pharma.

"Ron is a great partner to work with. His convictions and acumen played a major role as we established our technology platform for treating ALS and other major neurodegenerative disease," said Eran Ovadia, Immunity Pharma's founder and CEO.

About IPL344

IPL344 is Immunity Pharma lead drug candidate. IPL344 activates the PI3K-Akt signaling pathway in a variety of cells, including neurons, inducing pro-survival and anti-inflammatory processes. IPL344 is being developed as an intravenous injection for the treatment of ALS. IPL344 is planned to enter an open-label Phase 1/2a clinical trial in ALS patients.

About Immunity Pharma

Immunity Pharma Ltd. (IPL) is a privately-held clinical-stage neurology-focused biopharmaceutical company that develops therapies for neurodegenerative diseases, with an initial focus on Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. IPL’s drugs are biologically active peptides that stimulate therapeutic cell-signaling processes which are down-regulated in neurodegenerative diseases. These drugs mitigate progression of neurodegenerative diseases by inducing survival-supporting processes, including reduction of inflammation and reduction of programed cell death (apoptosis).

For more information please visit www.immunitypharma.com